We are pleased to announce that we now accept all major credit cards, as well as HSA and FSA for payment!
Call Us Today!
Click here now
Click here now
Call Us Today!
Click here now
Click here now
Female low libido refers to reduced interest in sexual activity, thoughts, or intimacy. Desire naturally varies between women and may change throughout life, but a persistent decline can become concerning when it causes personal distress or affects well-being and relationships.
Female libido treatment is not limited to prescribing hormones or medication. The most effective approach begins by identifying possible hormonal, physical, emotional, medication-related, and relationship factors. Optimal Female & Men’s Wellness provides individualized evaluations for women who want to understand changes in sexual desire and explore appropriate treatment options.
There is no single amount of sexual desire that is considered normal. Some women want sexual activity frequently, while others experience desire less often. Desire may also develop after intimacy or physical stimulation begins rather than appearing spontaneously.
A decrease may be temporary during periods of stress, illness, pregnancy, breastfeeding, relationship changes, or exhaustion. It may become a health concern when it lasts, differs noticeably from a woman’s previous level of interest, and causes distress.
Low desire is sometimes part of hypoactive sexual desire disorder, or HSDD. This involves an ongoing lack of sexual thoughts or interest that causes significant distress and is not better explained by another health condition, medication, relationship concern, or substance.
Sexual desire is influenced by a combination of biological, psychological, and social factors. Hormonal changes during perimenopause and menopause may contribute, especially when they occur alongside hot flashes, poor sleep, vaginal dryness, or pain during sex.
Other possible contributors include thyroid disease, diabetes, chronic pain, depression, anxiety, fatigue, body-image concerns, relationship conflict, and previous negative sexual experiences. Pregnancy, childbirth, and breastfeeding may also temporarily affect desire.
Some medications can influence libido. Antidepressants, blood pressure medications, hormonal contraceptives, sedatives, and certain pain medications may play a role for some patients. Women should not stop a prescribed medication without first discussing it with a qualified healthcare professional.
Sexual pain can also reduce desire. When intimacy is uncomfortable because of vaginal dryness, pelvic floor tension, infection, or another condition, avoiding sexual activity may become a protective response rather than a primary desire disorder.
A female libido treatment plan should begin with a confidential discussion about symptoms, health history, medications, menstrual patterns, menopause status, relationships, stress, sleep, and sexual comfort.
The evaluation may explore whether the change is generalized or limited to a particular situation. A clinician may also ask when the concern began, whether it causes distress, and whether arousal, orgasm, or pain are involved.
Laboratory testing may be appropriate when symptoms suggest thyroid dysfunction, anemia, metabolic concerns, menopause-related changes, or another medical issue. However, a single testosterone level does not diagnose low libido in women.
A pelvic examination or referral may be recommended when vaginal dryness, bleeding, discharge, pelvic pain, or painful intercourse is present. Understanding the complete pattern helps ensure that treatment addresses the actual barriers to desire.
Treatment may begin by addressing contributing concerns rather than targeting desire directly. Improving sleep, treating vaginal dryness, reviewing medications, managing mood symptoms, or addressing relationship stress may lead to meaningful improvement.
Counseling, cognitive behavioral therapy, mindfulness-based treatment, or sex therapy may help women understand desire patterns, improve communication, and reduce anxiety related to intimacy. Pelvic floor therapy may be appropriate when muscle tension or pain is involved.
For women experiencing menopause-related vaginal discomfort, lubricants, vaginal moisturizers, or prescription vaginal treatment may make intimacy more comfortable. Menopause hormone therapy may indirectly support sexual well-being when hot flashes, poor sleep, or vaginal symptoms contribute to low interest, but it is not a universal medication for libido.
Prescription medication may be considered for certain women with carefully evaluated HSDD.
Flibanserin is a daily oral female low libido medication approved for women younger than 65 with acquired, generalized HSDD. It is not intended to enhance sexual performance or treat low desire caused primarily by a medical condition, psychiatric concern, relationship issue, or medication.
Flibanserin can cause dizziness, sleepiness, low blood pressure, or fainting. Alcohol use, liver impairment, and interactions with certain medications require careful review.
Bremelanotide is an injectable medication used as needed before anticipated sexual activity. It is approved for certain premenopausal women with acquired, generalized HSDD. It is not intended for postmenopausal women or as a general sexual-performance enhancer.
Potential side effects include nausea, flushing, headache, and temporary increases in blood pressure. Women with uncontrolled high blood pressure or known cardiovascular disease may not be appropriate candidates.
Medication should only be selected after reviewing the expected benefits, limitations, possible side effects, medical history, and current prescriptions.
Testosterone therapy may be considered off-label for select women, particularly postmenopausal women with HSDD who have completed a thorough biopsychosocial evaluation.
Testosterone therapy for women is not approved in the United States specifically for low libido, and products designed for men can provide excessive doses if they are not carefully adjusted. Treatment should aim to keep levels within the expected female physiological range.
Possible side effects include acne, increased facial or body hair, and scalp hair changes. Voice changes or other androgen-related effects may occur with excessive exposure. Long-term safety information remains limited, making appropriate dosing and monitoring essential.
Testosterone should not be prescribed solely because a laboratory result appears low, nor should it be promoted as a general treatment for fatigue, weight loss, brain fog, or anti-aging.
At Optimal Female & Men’s Wellness, female libido treatment begins by listening to the patient’s experience without assuming that one hormone or medication explains every concern.
Care may include medication management, menopause support, evaluation of hormonal or thyroid concerns, treatment for vaginal dryness, nutritional guidance, or coordination with a gynecologist, pelvic floor therapist, or sexual-health professional.
Follow-up is important because treatment response can change over time. Medication effectiveness, side effects, comfort, and personal goals should be reviewed to determine whether the plan remains appropriate.
Changes in sexual desire can be difficult to discuss, but they are a valid part of overall health. A personalized evaluation can help identify whether hormones, medications, discomfort, stress, sleep, or another factor may be affecting intimacy.
Schedule an appointment with Optimal Female & Men’s Wellness to explore female libido treatment and determine whether hormone support, female low libido medication, or another individualized approach may be right for you.
Possible causes include menopause, vaginal dryness, poor sleep, stress, depression, thyroid disease, medication effects, relationship concerns, chronic illness, and sexual pain.
No. Desire varies naturally. It may be considered a disorder when the decline is persistent, causes distress, and is not better explained by another concern.
HSDD is an ongoing lack of sexual desire that causes significant personal distress and is not primarily caused by a medical condition, medication, relationship issue, or substance.
Female libido treatment may include medication review, counseling, treatment for vaginal dryness, hormone support, lifestyle changes, sex therapy, or prescription medication.
Yes. Flibanserin is approved for qualifying women younger than 65 with acquired, generalized HSDD. Bremelanotide is approved for qualifying premenopausal women.
Yes. Hormonal changes, hot flashes, sleep problems, vaginal dryness, and painful sex during menopause may contribute to reduced desire.
Estrogen is not primarily a libido medication, but it may improve vaginal comfort, sleep, or hot flashes that interfere with sexual interest.
Testosterone may be considered off-label for select women with carefully evaluated HSDD, particularly after menopause. Monitoring is required.
Some antidepressants may reduce desire, arousal, or orgasm. Medication should not be stopped abruptly; alternatives or adjustments should be discussed with a clinician.
Consider an evaluation when reduced desire persists, causes distress, affects a relationship, or occurs with pain, vaginal dryness, fatigue, mood changes, or other symptoms.